Efficacy News and Research

RSS
Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

New approach reduces JAK2 activity by pharmacologically targeting HSP90 protein

New approach reduces JAK2 activity by pharmacologically targeting HSP90 protein

Excelimmune presents positive results for HRPA therapy against MRSA infections

Excelimmune presents positive results for HRPA therapy against MRSA infections

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

Switching ACS patients to Effient therapy reduces Maximum Platelet Aggregation

AGTC receives grant to evaluate Phase II Human Clinical Trial for LCA retinal disease

AGTC receives grant to evaluate Phase II Human Clinical Trial for LCA retinal disease

St. John Hospital commences enrollment in CONNECT trial for peripheral artery disease

St. John Hospital commences enrollment in CONNECT trial for peripheral artery disease

Ironwood, Forest Laboratories announce positive results for linaclotide Phase 3 clinical trials in IBS-C patients

Ironwood, Forest Laboratories announce positive results for linaclotide Phase 3 clinical trials in IBS-C patients

Capstone Therapeutics reaches overall progress in AZX100 Phase 2a clinical trials for keloid scarring

Capstone Therapeutics reaches overall progress in AZX100 Phase 2a clinical trials for keloid scarring

Complementary medicine to save millions: Report

Complementary medicine to save millions: Report

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Relypsa completes $70M Series B financing

Relypsa completes $70M Series B financing

FDA updates Shire's ProAmatine medicine for symptomatic orthostatic hypotension treatment

FDA updates Shire's ProAmatine medicine for symptomatic orthostatic hypotension treatment

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

AB SCIEX, University of Melbourne join to develop drug metabolism studies of biopharmaceuticals

AB SCIEX, University of Melbourne join to develop drug metabolism studies of biopharmaceuticals

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.